Efficacy of SALI-10 Oral Probiotics in Experimental Gingivitis
NCT ID: NCT07256743
Last Updated: 2025-12-01
Study Results
Results pending
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
Recruitment Status
RECRUITING
Clinical Phase
PHASE2
Total Enrollment
60 participants
Study Classification
INTERVENTIONAL
Study Start Date
2025-09-01
Study Completion Date
2026-06-01
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Gingivitis is among the most prevalent oral diseases worldwide, affecting an estimated 50-90% of adults. It is a reversible condition primarily caused by microbial plaque accumulation on teeth and gingival surfaces, which triggers inflammation. Standard care emphasizes plaque reduction through oral hygiene, and research shows gingivitis can be reversed once hygiene resumes. The classic experimental gingivitis (EG) model developed in 1965 by Löe and Silness demonstrated the direct link between plaque buildup and gingival inflammation, further confirming that gingival health can be restored after resuming proper care.
Microbial ecology shifts are central to gingivitis pathogenesis. In health, the oral microbiome is dominated by gram-positive Streptococcus species. With plaque accumulation, microbial communities transition to gram-negative periopathogens such as Porphyromonas, Tannerella, Treponema, and Prevotella. This dysbiosis provokes heightened inflammation, tissue damage, and, in susceptible individuals, progression to periodontitis. Individual variability in the inflammatory response has been associated with differences in the presence and activity of beneficial streptococci. Certain strains of Streptococcus salivarius produce lantibiotics called salivaricins-polycyclic antimicrobial peptides containing lanthionine residues. Salivaricins inhibit oral pathogens and have been investigated for their antimicrobial and probiotic properties, particularly in the context of rising antibiotic resistance. Probiotic S. salivarius strains isolated from healthy individuals have demonstrated safety and antimicrobial potential in previous studies, supporting their use in preventing oral and respiratory infections.
A strain of S. salivarius designated SALI-10 produces a lantibiotic, Salivaricin 10, and is being evaluated as a candidate for gingivitis prevention. This strain is hypothesized to (1) help stabilize populations of beneficial streptococci during plaque accumulation, (2) competitively inhibit periopathogens such as Porphyromonas and Prevotella, and (3) suppress the dysbiotic shift toward gram-negative dominance. By contributing to microbial balance and reducing inflammatory triggers, SALI-10 may support resilient host-microbe interactions associated with gingival health. This approach may offer a dual antimicrobial and microbiome-stabilizing strategy with relevance to gingivitis management and longer-term periodontal health.
Microbial ecology shifts are central to gingivitis pathogenesis. In health, the oral microbiome is dominated by gram-positive Streptococcus species. With plaque accumulation, microbial communities transition to gram-negative periopathogens such as Porphyromonas, Tannerella, Treponema, and Prevotella. This dysbiosis provokes heightened inflammation, tissue damage, and, in susceptible individuals, progression to periodontitis. Individual variability in the inflammatory response has been associated with differences in the presence and activity of beneficial streptococci. Certain strains of Streptococcus salivarius produce lantibiotics called salivaricins-polycyclic antimicrobial peptides containing lanthionine residues. Salivaricins inhibit oral pathogens and have been investigated for their antimicrobial and probiotic properties, particularly in the context of rising antibiotic resistance. Probiotic S. salivarius strains isolated from healthy individuals have demonstrated safety and antimicrobial potential in previous studies, supporting their use in preventing oral and respiratory infections.
A strain of S. salivarius designated SALI-10 produces a lantibiotic, Salivaricin 10, and is being evaluated as a candidate for gingivitis prevention. This strain is hypothesized to (1) help stabilize populations of beneficial streptococci during plaque accumulation, (2) competitively inhibit periopathogens such as Porphyromonas and Prevotella, and (3) suppress the dysbiotic shift toward gram-negative dominance. By contributing to microbial balance and reducing inflammatory triggers, SALI-10 may support resilient host-microbe interactions associated with gingival health. This approach may offer a dual antimicrobial and microbiome-stabilizing strategy with relevance to gingivitis management and longer-term periodontal health.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Impact of Oral Probiotics on Oral Homeostasis
NCT04071210
Gingivitis
COMPLETED
NA
The Effect of Probiotics on Gingivitis
NCT05727436
Gingivitis; Chronic
COMPLETED
NA
Clinical Effect of Lactobacillus Reuteri in Treatment of Gingivitis
NCT02801773
Gingivitis
UNKNOWN
PHASE2
To Evaluate the Efficacy of Probiotics Toothpastes in Improvement of Gingivitis and Prevention of Periodontal Diseases Via Modulating the Oral Microbiota
NCT04190485
Gingivitis
COMPLETED
NA
Effects on Tablets Containing Probiotic Candidate Strains
NCT02633345
Gingivitis
COMPLETED
NA
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Gingivitis is an oral disease condition affecting 50% to 90% of adults globally. The gingivitis pathology can be reversed by reduction or removal of microbial plaque that accumulates on hard and soft tissues and is considered standard of care in the industry. Regular oral hygiene in combination with therapeutics that delivers an anti-microbial benefit is thought to mitigate the onset of gingivitis. However, testing therapeutics for prophylaxis benefit to mitigate development of gingivitis has not been fully examined.
The classical model of experimental gingivitis (EG) was developed in 1965 by Loe and Silness who convincingly demonstrated the causative relationship between the accumulation of dental plaque and the development of clinically evident gingivitis in healthy young adults abstaining from all oral hygiene practices for a 21-day period. Furthermore, on resuming customary oral hygiene practices, all subjects demonstrated a return to gingival health. Understanding how participants returned quickly to gingival health aligns with the current understanding that the clinically healthy state is an active and dynamic process.
Neutrophils, a type of white blood cell (leukocyte), represent a key component of the innate defence system that protects periodontal tissue from both gingivitis and periodontitis. Not only are they the first line of cellular defence, but they are among the most abundant leukocytes within the periodontal tissues. Gingivitis is associated with a significant increase in the number of neutrophils that migrate to periodontal tissue. In contrast, individuals with too few neutrophils brought about by either congenital deficiencies in neutrophil numbers or transit (LAD 1 and 2), or those with induced neutropenia by chemical induction with antimitotic agents such as cyclophosphamide, invariably develop periodontitis. Likewise, studies in knockout mice that are defective in neutrophil transit also develop periodontitis. Consistent with the key contribution of neutrophils to both gingivitis and periodontitis, neutrophil transit to gingival tissue is highly regulated. The periodontium contains innate host defense mediators that facilitate the transit of neutrophils from the highly vascularized gingival tissue to the gingival crevice, where they form a "wall" between the host tissue and the dental plaque biofilm.
However, the prolonged presence of neutrophils in gingival tissue is not tolerated in the healthy state. The failure to downregulate neutrophil transit results in an increase in neutrophil numbers in gingival tissue and a significant increase in periodontal bone loss. Therefore, neutrophil homing to the gingival crevice is highly regulated such that under conditions of periodontal health the appropriate amount of neutrophils are present to maintain control of dental plaque bacterial growth and yet not elicit tissue damage. Evaluation of oral and blood neutrophils during experimental gingivitis has shown that people with uniquely high inflammatory response have an exaggerated polymorphonuclear neutrophil response both in the oral cavity and in the blood.
Gingivitis is a reversible inflammatory condition caused by the accumulation of dental plaque and the associated disruption of the host-microbial homeostasis. During gingivitis, the microbial community transitions from being dominated by gram-positive health-associated bacteria, such as Streptococcus species, to gram-negative periopathogens, including species of the genera Porphyromonas, Tannerella, Treponema and Prevotella. This dysbiotic shift triggers inflammatory responses, leading to tissue damage and, in some cases, progression to periodontitis.
A recent study on human experimental gingivitis identified three distinct host response phenotypes-high, low, and slow responders-based on clinical, inflammatory, and microbial parameters:
High Responders: Rapid plaque accumulation accompanied by a significant increase in gram-negative periopathogens and elevated inflammatory markers, such as interleukin-1β (IL-1β).
Low Responders: Similar plaque accumulation to high responders but lower inflammation, suggesting a more muted host response to bacterial dysbiosis.
Slow Responders: Delayed plaque accumulation and microbial succession, with prolonged dominance of health-associated Streptococcus species and a delayed or reduced inflammatory response.
Microbial analysis revealed that the persistence of beneficial Streptococcus species, such as S. sanguinis and S. oralis, in slow and low responders correlates with a protective effect against the emergence of periopathogens and the associated inflammatory cascade. Conversely, the loss of these beneficial bacteria in high responders was linked to more severe inflammation, highlighting the critical role of the oral microbiome in modulating gingivitis severity.
Lantibiotic salivaricins are polycyclic peptides containing lanthionine and/or β-methyllanthionine residues that are produced by certain strains of Streptococcus salivarius, which almost exclusively reside in the human oral cavity. These molecules are notable for their antimicrobial activity toward relevant oral pathogens, supporting the development of salivaricin-producing probiotic strains. Salivaricins are also relevant for development of novel antibacterial therapies in the context of emerging antibiotic resistance. Previous work has shown the bacteriocin and safety features of S. salivarius strains isolated from healthy subjects, demonstrating their potential for use as probiotics.
Proposed Solution: S. salivarius SALI-10
The investigators propose using a novel strain, Streptococcus salivarius SALI-10, as a targeted microbial intervention to modulate the oral microbiome and prevent gingivitis. S. salivarius SALI-10 is hypothesized to:
* Maintain a stable population of beneficial streptococci during plaque accumulation.
* Inhibit the growth of periopathogens through microbial competition and production of Salivaricin 10.
* Delay or suppress the dysbiotic shift to gram-negative dominance, thereby reducing the inflammatory response.
By supporting microbial homeostasis, SALI-10 may emulate the resilience observed in slow responders and offer a novel strategy for gingivitis prevention.
Dosage Regimen
This is a placebo-controlled study. Each participant randomized to the intervention group will receive mint-flavoured SALI-10 lozenges. They will take one lozenge twice a day-morning and evening-after brushing, allowing it to dissolve in the mouth. Participants will use the study lozenges throughout the study.
Prestudy Screening and Baseline Evaluation Telephone Pre-Screening
Potential study participants who express interest will be contacted by telephone. Eligibility for screening will be assessed using standard recruitment questions.
In-Person Screening
Before screening procedures occur, participants will provide informed consent. Participants will complete demographic and health information and undergo an oral examination of soft and hard tissues. Female participants will undergo a urine pregnancy test. The screening continues until sixty (60) participants are enrolled.
Visit 1 - Baseline Assessment
Participants will undergo an oral exam including probing depth (PD), attachment level (AL), visible plaque index (VPI), gingival index (GI), and bleeding on probing (BOP). Biospecimens collected will include gingival crevicular fluid (GCF), subgingival plaque, saliva, and an oral rinse. Participants will receive a dental cleaning and their assigned study product with instructions.
Treatment Visit Schedule
Participants will consume two lozenges per day at home and attend eight (8) study visits.
Visit 2 (Day -14 / -7)
Oral examination and biospecimen collection (GCF, plaque, saliva, oral rinse). Participants report use of NHPs and adverse effects.
Induction Phase (No Oral Hygiene for 21 Days) Visit 3 (Day 0)
Oral examination and biospecimen collection. Participants refrain from all oral hygiene for 21 days and continue their assigned lozenges.
Visit 4 (Day 7)
Oral examination and biospecimen collection. Participants are reminded to continue refraining from oral hygiene.
Visit 5 (Day 14)
Oral examination and biospecimen collection. Participants continue refraining from oral hygiene.
Resolution Phase (Participants Resume Oral Hygiene) Visit 6 (Day 21)
Oral examination and biospecimen collection. Participants receive a dental cleaning and resume home oral hygiene while continuing study lozenges.
Visit 7 (Day 28)
Oral examination and biospecimen collection.
Visit 8 - End of Study (Day 35)
Oral examination and biospecimen collection. Participants receive compensation and resume regular oral hygiene. After study completion, the manufacturer will unblind the product groups, and participants will be informed of their assignment.
The classical model of experimental gingivitis (EG) was developed in 1965 by Loe and Silness who convincingly demonstrated the causative relationship between the accumulation of dental plaque and the development of clinically evident gingivitis in healthy young adults abstaining from all oral hygiene practices for a 21-day period. Furthermore, on resuming customary oral hygiene practices, all subjects demonstrated a return to gingival health. Understanding how participants returned quickly to gingival health aligns with the current understanding that the clinically healthy state is an active and dynamic process.
Neutrophils, a type of white blood cell (leukocyte), represent a key component of the innate defence system that protects periodontal tissue from both gingivitis and periodontitis. Not only are they the first line of cellular defence, but they are among the most abundant leukocytes within the periodontal tissues. Gingivitis is associated with a significant increase in the number of neutrophils that migrate to periodontal tissue. In contrast, individuals with too few neutrophils brought about by either congenital deficiencies in neutrophil numbers or transit (LAD 1 and 2), or those with induced neutropenia by chemical induction with antimitotic agents such as cyclophosphamide, invariably develop periodontitis. Likewise, studies in knockout mice that are defective in neutrophil transit also develop periodontitis. Consistent with the key contribution of neutrophils to both gingivitis and periodontitis, neutrophil transit to gingival tissue is highly regulated. The periodontium contains innate host defense mediators that facilitate the transit of neutrophils from the highly vascularized gingival tissue to the gingival crevice, where they form a "wall" between the host tissue and the dental plaque biofilm.
However, the prolonged presence of neutrophils in gingival tissue is not tolerated in the healthy state. The failure to downregulate neutrophil transit results in an increase in neutrophil numbers in gingival tissue and a significant increase in periodontal bone loss. Therefore, neutrophil homing to the gingival crevice is highly regulated such that under conditions of periodontal health the appropriate amount of neutrophils are present to maintain control of dental plaque bacterial growth and yet not elicit tissue damage. Evaluation of oral and blood neutrophils during experimental gingivitis has shown that people with uniquely high inflammatory response have an exaggerated polymorphonuclear neutrophil response both in the oral cavity and in the blood.
Gingivitis is a reversible inflammatory condition caused by the accumulation of dental plaque and the associated disruption of the host-microbial homeostasis. During gingivitis, the microbial community transitions from being dominated by gram-positive health-associated bacteria, such as Streptococcus species, to gram-negative periopathogens, including species of the genera Porphyromonas, Tannerella, Treponema and Prevotella. This dysbiotic shift triggers inflammatory responses, leading to tissue damage and, in some cases, progression to periodontitis.
A recent study on human experimental gingivitis identified three distinct host response phenotypes-high, low, and slow responders-based on clinical, inflammatory, and microbial parameters:
High Responders: Rapid plaque accumulation accompanied by a significant increase in gram-negative periopathogens and elevated inflammatory markers, such as interleukin-1β (IL-1β).
Low Responders: Similar plaque accumulation to high responders but lower inflammation, suggesting a more muted host response to bacterial dysbiosis.
Slow Responders: Delayed plaque accumulation and microbial succession, with prolonged dominance of health-associated Streptococcus species and a delayed or reduced inflammatory response.
Microbial analysis revealed that the persistence of beneficial Streptococcus species, such as S. sanguinis and S. oralis, in slow and low responders correlates with a protective effect against the emergence of periopathogens and the associated inflammatory cascade. Conversely, the loss of these beneficial bacteria in high responders was linked to more severe inflammation, highlighting the critical role of the oral microbiome in modulating gingivitis severity.
Lantibiotic salivaricins are polycyclic peptides containing lanthionine and/or β-methyllanthionine residues that are produced by certain strains of Streptococcus salivarius, which almost exclusively reside in the human oral cavity. These molecules are notable for their antimicrobial activity toward relevant oral pathogens, supporting the development of salivaricin-producing probiotic strains. Salivaricins are also relevant for development of novel antibacterial therapies in the context of emerging antibiotic resistance. Previous work has shown the bacteriocin and safety features of S. salivarius strains isolated from healthy subjects, demonstrating their potential for use as probiotics.
Proposed Solution: S. salivarius SALI-10
The investigators propose using a novel strain, Streptococcus salivarius SALI-10, as a targeted microbial intervention to modulate the oral microbiome and prevent gingivitis. S. salivarius SALI-10 is hypothesized to:
* Maintain a stable population of beneficial streptococci during plaque accumulation.
* Inhibit the growth of periopathogens through microbial competition and production of Salivaricin 10.
* Delay or suppress the dysbiotic shift to gram-negative dominance, thereby reducing the inflammatory response.
By supporting microbial homeostasis, SALI-10 may emulate the resilience observed in slow responders and offer a novel strategy for gingivitis prevention.
Dosage Regimen
This is a placebo-controlled study. Each participant randomized to the intervention group will receive mint-flavoured SALI-10 lozenges. They will take one lozenge twice a day-morning and evening-after brushing, allowing it to dissolve in the mouth. Participants will use the study lozenges throughout the study.
Prestudy Screening and Baseline Evaluation Telephone Pre-Screening
Potential study participants who express interest will be contacted by telephone. Eligibility for screening will be assessed using standard recruitment questions.
In-Person Screening
Before screening procedures occur, participants will provide informed consent. Participants will complete demographic and health information and undergo an oral examination of soft and hard tissues. Female participants will undergo a urine pregnancy test. The screening continues until sixty (60) participants are enrolled.
Visit 1 - Baseline Assessment
Participants will undergo an oral exam including probing depth (PD), attachment level (AL), visible plaque index (VPI), gingival index (GI), and bleeding on probing (BOP). Biospecimens collected will include gingival crevicular fluid (GCF), subgingival plaque, saliva, and an oral rinse. Participants will receive a dental cleaning and their assigned study product with instructions.
Treatment Visit Schedule
Participants will consume two lozenges per day at home and attend eight (8) study visits.
Visit 2 (Day -14 / -7)
Oral examination and biospecimen collection (GCF, plaque, saliva, oral rinse). Participants report use of NHPs and adverse effects.
Induction Phase (No Oral Hygiene for 21 Days) Visit 3 (Day 0)
Oral examination and biospecimen collection. Participants refrain from all oral hygiene for 21 days and continue their assigned lozenges.
Visit 4 (Day 7)
Oral examination and biospecimen collection. Participants are reminded to continue refraining from oral hygiene.
Visit 5 (Day 14)
Oral examination and biospecimen collection. Participants continue refraining from oral hygiene.
Resolution Phase (Participants Resume Oral Hygiene) Visit 6 (Day 21)
Oral examination and biospecimen collection. Participants receive a dental cleaning and resume home oral hygiene while continuing study lozenges.
Visit 7 (Day 28)
Oral examination and biospecimen collection.
Visit 8 - End of Study (Day 35)
Oral examination and biospecimen collection. Participants receive compensation and resume regular oral hygiene. After study completion, the manufacturer will unblind the product groups, and participants will be informed of their assignment.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Gingivitis
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
Allocation Method
RANDOMIZED
Intervention Model
PARALLEL
Once a participant volunteers they begin with a baseline visit. They receive a full oral assessment (probing depth, attachment level, plaque, gingival and bleeding indices) and biospecimen collection (gingival crevicular fluid, plaque, saliva, rinse); and is then assigned a study product: two lozenges (either active or placebo) daily for 14 days, taken after brushing, with instructions to maintain hygiene and return lozenge containers for compliance.
Participants attend eight visits. At each, containers are returned, oral exams repeated, biospecimens collected, and questionnaires completed on product use and adverse events. During the induction phase (Day 0-21), subjects refrain from oral hygiene while continuing lozenges twice daily. On Day 21, participants receive prophylaxis and resume oral hygiene while continuing lozenges for two weeks.
Participants attend eight visits. At each, containers are returned, oral exams repeated, biospecimens collected, and questionnaires completed on product use and adverse events. During the induction phase (Day 0-21), subjects refrain from oral hygiene while continuing lozenges twice daily. On Day 21, participants receive prophylaxis and resume oral hygiene while continuing lozenges for two weeks.
Primary Study Purpose
PREVENTION
Blinding Strategy
QUADRUPLE
Participants
Caregivers
Investigators
Outcome Assessors
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Placebo
Placebo lozenges used
Group Type
NO_INTERVENTION
No interventions assigned to this group
SALI-10
Lozenges containing 6B CFUs of
Group Type
ACTIVE_COMPARATOR
6B SALI-10
Intervention Type
DIETARY_SUPPLEMENT
Lozenges containing 6B CFUs of probiotic S. salivarius SALI-10
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
6B SALI-10
Lozenges containing 6B CFUs of probiotic S. salivarius SALI-10
Intervention Type
DIETARY_SUPPLEMENT
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
1. Male or female volunteers aged 18-70 years
2. In good general health, ASA I
3. No clinical signs of gingival inflammation at \>90% of sites observed
4. Absence of Periodontal Pockets, Probing Depth (PD) \< 3.0 mm on all teeth/site
5. Absence of Clinical Attachment Loss (CAL) = 0 mm
6. No periodontal disease history
7. Have at least 20 gradeable teeth
8. Non-smokers
9. Fluent in English
10. For study participants of childbearing potential, both men and women, at least one of the following birth control measures must be used: abstinence, hormonal birth control (oral, injectable, transdermal, intra-vaginal), intrauterine devices, confirmed successful vasectomy, or condoms.
2. In good general health, ASA I
3. No clinical signs of gingival inflammation at \>90% of sites observed
4. Absence of Periodontal Pockets, Probing Depth (PD) \< 3.0 mm on all teeth/site
5. Absence of Clinical Attachment Loss (CAL) = 0 mm
6. No periodontal disease history
7. Have at least 20 gradeable teeth
8. Non-smokers
9. Fluent in English
10. For study participants of childbearing potential, both men and women, at least one of the following birth control measures must be used: abstinence, hormonal birth control (oral, injectable, transdermal, intra-vaginal), intrauterine devices, confirmed successful vasectomy, or condoms.
Exclusion Criteria
1. Presence of orthodontic bands.
2. Presence of partial or full dentures.
3. Tumour(s) of the soft or the hard tissues of the oral cavity.
4. Cavitated carious lesions requiring immediate restorative treatment.
5. History of allergy to a consumer or personal care products or dentifrice ingredients as determined by the dental profession monitoring the study.
6. Participation in any other clinical study or test panel within one month before entering the study.
7. Medical condition which requires pre-medication before dental visits/procedures
8. Current use of anti-inflammatory, antibiotics, or antimicrobial drugs or within the last 30 days of enrolment.
9. History of periodontal disease.
10. History of systemic inflammatory, immune conditions and immunocompromised conditions
11. Pregnant or nursing women or those planning to get pregnant
12. Use of tobacco products.
13. Long-term antibiotic or anti-inflammatory therapy.
14. Medication or Natural Health Products (NHPs) that could affect the gingiva like calcium channel blockers, anti-epileptic therapy etc.
15. Medical condition or any current usage of medication that the investigator considers may compromise the study participant's safety as well as the quality of the study results
16. Allergy to any of the following ingredients: Streptococcus Salivarius, Sorbitol, Isomalt, Calcium phosphate dibasic, Potato starch, Mint, Glyceryl dibehenate, Stevia, Maltodextrin
17. Use of other probiotics
18. Taking anticoagulant medications and those suffering from blood and bleeding disorders
19. Recently experienced or will be experiencing dental, oral or any type of surgery.
20. Use of anti-plaque/ anti-gingivitis products
21. Presence of active infections
22. Participants who are experiencing nausea, fever, vomiting, bloody diarrhoea or severe abdominal pain.
23. Use of any antibiotics.
2. Presence of partial or full dentures.
3. Tumour(s) of the soft or the hard tissues of the oral cavity.
4. Cavitated carious lesions requiring immediate restorative treatment.
5. History of allergy to a consumer or personal care products or dentifrice ingredients as determined by the dental profession monitoring the study.
6. Participation in any other clinical study or test panel within one month before entering the study.
7. Medical condition which requires pre-medication before dental visits/procedures
8. Current use of anti-inflammatory, antibiotics, or antimicrobial drugs or within the last 30 days of enrolment.
9. History of periodontal disease.
10. History of systemic inflammatory, immune conditions and immunocompromised conditions
11. Pregnant or nursing women or those planning to get pregnant
12. Use of tobacco products.
13. Long-term antibiotic or anti-inflammatory therapy.
14. Medication or Natural Health Products (NHPs) that could affect the gingiva like calcium channel blockers, anti-epileptic therapy etc.
15. Medical condition or any current usage of medication that the investigator considers may compromise the study participant's safety as well as the quality of the study results
16. Allergy to any of the following ingredients: Streptococcus Salivarius, Sorbitol, Isomalt, Calcium phosphate dibasic, Potato starch, Mint, Glyceryl dibehenate, Stevia, Maltodextrin
17. Use of other probiotics
18. Taking anticoagulant medications and those suffering from blood and bleeding disorders
19. Recently experienced or will be experiencing dental, oral or any type of surgery.
20. Use of anti-plaque/ anti-gingivitis products
21. Presence of active infections
22. Participants who are experiencing nausea, fever, vomiting, bloody diarrhoea or severe abdominal pain.
23. Use of any antibiotics.
Minimum Eligible Age
18 Years
Maximum Eligible Age
70 Years
Eligible Sex
ALL
Accepts Healthy Volunteers
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
University of Toronto
OTHER
Sponsor Role
collaborator
Ostia Sciences
INDUSTRY
Sponsor Role
lead
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Responsibility Role
SPONSOR
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Dr. Michael Goldberg, MDM
Role: PRINCIPAL_INVESTIGATOR
University of Toronto
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
University of Toronto
Toronto, Ontario, Canada
Site Status
RECRUITING
Countries
Review the countries where the study has at least one active or historical site.
Canada
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
References
Explore related publications, articles, or registry entries linked to this study.
Wellappuli NC, Fine N, Lawrence HP, Goldberg M, Tenenbaum HC, Glogauer M. Oral and Blood Neutrophil Activation States during Experimental Gingivitis. JDR Clin Trans Res. 2018 Jan;3(1):65-75. doi: 10.1177/2380084417742120. Epub 2017 Nov 20.
Reference Type
BACKGROUND
van der Weijden F, Slot DE. Oral hygiene in the prevention of periodontal diseases: the evidence. Periodontol 2000. 2011 Feb;55(1):104-23. doi: 10.1111/j.1600-0757.2009.00337.x. No abstract available.
Reference Type
BACKGROUND
LOE H, THEILADE E, JENSEN SB. EXPERIMENTAL GINGIVITIS IN MAN. J Periodontol (1930). 1965 May-Jun;36:177-87. doi: 10.1902/jop.1965.36.3.177. No abstract available.
Reference Type
BACKGROUND
Kerns KA, Bamashmous S, Hendrickson EL, Kotsakis GA, Leroux BG, Daubert DD, Roberts FA, Chen D, Trivedi HM, Darveau RP, McLean JS. Localized microbially induced inflammation influences distant healthy tissues in the human oral cavity. Proc Natl Acad Sci U S A. 2023 Oct 10;120(41):e2306020120. doi: 10.1073/pnas.2306020120. Epub 2023 Oct 2.
Reference Type
BACKGROUND
Gunsolley JC. A meta-analysis of six-month studies of antiplaque and antigingivitis agents. J Am Dent Assoc. 2006 Dec;137(12):1649-57. doi: 10.14219/jada.archive.2006.0110.
Reference Type
BACKGROUND
Gallagher H, Ramsay SC, Barnes J, Maggs J, Cassidy N, Ketheesan N. Neutrophil labeling with [(99m)Tc]-technetium stannous colloid is complement receptor 3-mediated and increases the neutrophil priming response to lipopolysaccharide. Nucl Med Biol. 2006 Apr;33(3):433-9. doi: 10.1016/j.nucmedbio.2005.12.014. Epub 2006 Mar 9.
Reference Type
BACKGROUND
Berezow AB, Darveau RP. Microbial shift and periodontitis. Periodontol 2000. 2011 Feb;55(1):36-47. doi: 10.1111/j.1600-0757.2010.00350.x. No abstract available.
Reference Type
BACKGROUND
Barbour A, Wescombe P, Smith L. Evolution of Lantibiotic Salivaricins: New Weapons to Fight Infectious Diseases. Trends Microbiol. 2020 Jul;28(7):578-593. doi: 10.1016/j.tim.2020.03.001. Epub 2020 Apr 6.
Reference Type
BACKGROUND
Barbour A, Philip K. Variable characteristics of bacteriocin-producing Streptococcus salivarius strains isolated from Malaysian subjects. PLoS One. 2014 Jun 18;9(6):e100541. doi: 10.1371/journal.pone.0100541. eCollection 2014.
Reference Type
BACKGROUND
Albandar JM, Rams TE. Global epidemiology of periodontal diseases: an overview. Periodontol 2000. 2002;29:7-10. doi: 10.1034/j.1600-0757.2002.290101.x. No abstract available.
Reference Type
BACKGROUND
Provided Documents
Download supplemental materials such as informed consent forms, study protocols, or participant manuals.
Document Type: Study Protocol and Informed Consent Form
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
OstiaGingivitis
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.
Colonisation Efficacy of a Probiotic Chewing Gum.
NCT05624177
UNKNOWN
NA
Effect of Probiotics on Oral Homeostasis During Oral Hygiene Discontinuation
NCT05268757
COMPLETED
NA
Effect of Probiotic Lozenges on Halitosis in Patients With Chronic Periodontitis
NCT02789436
UNKNOWN
PHASE4
Effects of Prebiotic Oral Healthcare Products as an Adjunct to Non-surgical Periodontal Therapy
NCT02520375
WITHDRAWN
NA
Effect of Probiotic on the Plaque pH. A Randomized Double Blind Interventional Study
NCT01601145
COMPLETED
PHASE4
Probiotic Toothpaste for Microbial Colonization
NCT05480020
UNKNOWN
NA
Effect of TCI188 Probiotic on Oral Health
NCT06141083
RECRUITING
NA
Effect of a Probiotic Water on Oral Health in Adults
NCT04473404
COMPLETED
NA
The Effect of Probiotics on Gums Health and Bad Breath
NCT06910397
COMPLETED
NA
Effects of a Composition on the Oral Microbiome, pH, Nitrite/Nitrate Ratio, Elastases and Inflammation in Oral Dysbiosis
NCT05463484
COMPLETED
PHASE2/PHASE3
The Use of Chlorhexidine and a Probiotic Lozenge in the Nonsurgical Therapy of Periodontitis
NCT05548361
COMPLETED
NA
The Effect of Probiotics on Gingivitis: Part 2
NCT05919134
COMPLETED
NA
Evaluation of the Efficacy of Probiotics in Chronic Periodontitis Patients
NCT02390687
COMPLETED
PHASE3
A Clinical Trial to Evaluate Long-term Efficacy and Safety of Lozenges Containing Lactobacilli Reuteri (Prodentis™) on Gingivitis
NCT01811316
COMPLETED
NA
Propolis Extract, Nanovitamin C and Nanovitamin E on Desquamative Gingivitis
NCT05124366
UNKNOWN
NA
Efficacy of a Rinse Containing Sea Salt and Lysozyme on Biofilm and Gingival Health
NCT03329105
COMPLETED
NA
Effect of Probiotics as Supplement to Non-surgical Periodontal Treatment
NCT05518747
UNKNOWN
NA
Effect of an Oral Probiotic Tablet on Oral Bacteria and Clinical Measurements (ProBiora3)
NCT01520974
UNKNOWN
NA
The Effects of an Oral Probiotic Intervention With or Without a Novel ADP-1 Toothpaste
NCT05330793
COMPLETED
NA
Effectiveness of Coenzyme Q10 and Probiotics in Periodontal Therapy During Pregnancy
NCT07029360
RECRUITING
NA
Evaluation of The Effect of Live Probiotic Cultures Present in Fermented Dairy Product (Yogurt) Versus The Effect of Freeze-Dried Probiotic Sachets on Gingival Bleeding of Adolescents
NCT03640065
COMPLETED
PHASE4
Effect Of A Locally Delivered Probiotic Sacchraomyces Boulardii In The Management Of Chronic Periodontitis
NCT03516370
COMPLETED
PHASE1/PHASE2
Effects of a Probiotic on Oral Microbiota and Glycemic Control in Type 2 Diabetics; A Randomized Clinical Trial
NCT04913909
COMPLETED
NA
A Study of Virtually Supervised Mouthwash and Interdental Brushes
NCT05756673
COMPLETED
PHASE4